Divine Aleru, Microbiome Signatures Research Coordinator

This study evaluates the use of intravaginal boric acid for recurrent vulvovaginal candidiasis and bacterial vaginosis, highlighting its long-term tolerability, high patient satisfaction, and rare side effects.

Cannabidiol (BD) shows promise as a microbiome-targeted intervention for bacterial vaginosis (V). It reduces Gardnerella vaginalis viability, disrupts biofilms, and promotes Lactobacillus restoration. BD’s antimicrobial, anti-inflammatory, and antioxidant properties support its effectiveness, reinforcing the V microbiome signature’s clinical accuracy and its potential as a viable treatment option.

This study identifies phospho-2-dehydro-3-deoxyheptonate aldolase as a drug target in Gardnerella vaginalis and highlights five DA-approved compounds as potential treatments for bacterial vaginosis.

This study explores the link between vaginal microbiota and recurrent spontaneous abortion (SA), showing that drug treatment, including metformin combined with aspirin, can alter microbiota composition and potentially improve pregnancy outcomes by increasing Lactobacillus abundance.

This study identifies AHP synthase as a promising drug target for Gardnerella vaginalis in the treatment of bacterial vaginosis, presenting potential inhibitors with favorable pharmacokinetics.

BD shows antibacterial and antibiofilm activity against Gardnerella vaginalis, suggesting its potential as a novel treatment for bacterial vaginosis, particularly in biofilm-related infections.

The study analyzed the genetic evolution of Gardnerella vaginalis, focusing on its resistance and virulence under Darwinian positive selection. It identifies new drug targets and emphasizes the pathogen’s evolving resistance mechanisms.

V disrupts Lactobacillus dominance, increasing infertility risk via inflammation, ID, and endometritis. L. crispatus probiotics reduce V recurrence; E treatment boosts VF success. Early screening and microbiome-targeted therapies are vital to prevent reproductive complications.

Study links V and past chlamydial infection to tubal infertility, with 87.5% of V-positive women having tubal damage. Both infections were often asymptomatic. VF pregnancy rates were unaffected, but V showed lower implantation trends. Findings highlight V’s role in infertility, urging early screening to prevent tubal damage.

This review links V recurrence to resilient biofilms formed by Gardnerella vaginalis. Probiotics and biofilm disruptors (e.g., Astodrimer gel) improve outcomes by restoring Lactobacillus dominance. Current antibiotics fail to penetrate biofilms, necessitating multimodal therapies. Future research should explore MT and microbiome-targeted interventions for sustained V remission.